TH85131A

TH85131A - Microbial-killing compounds containing pyrimidine or thiazine

Info

Publication number: TH85131A
Application number: TH301001744A
Authority: TH
Inventors: มาร์เซล แวน รอย เจมส์; สท็อฟเฟลส์ พอล; ปีแอร์ ทีเอ็มเอ็มจีเดอ เบธูน มารี
Original assignee: แจนส์เซ่น ไซเอนซ์ส์ ไอร์แลนด์ ยูซี; นางสาวปรับโยชน์ ศรีกิจจาภรณ์; นายจักรพรรดิ์ มงคลสิทธิ์; นายรุทร นพคุณ
Filing date: 2003-05-12
Publication date: 2007-06-21

Abstract

DC60 (06/08/46) การประดิษฐ์นี้เกี่ยวข้องกับแอคติวิตีการฆ่าจุลินทรีย์ของสารยับยั้งรีเวอร์สทรานสคริพเทสที่ ไม่ใช่นิวคลีโอไซด์ซึ่งมีไพริมิดีนหรือไทรอะซีน สารประกอบของการประดิษฐ์นี้ยับยั้งการติดเชื้อ ซิสเตมิคของคนโดย HIV โดยเฉพาะสารประกอบนี้ป้องกันการแพร่โดยทางเพศของ HIV ในคน การประดิษฐ์นี้เกี่ยวข้องกับแอคติวิตีการฆ่าจุลินทรีย์ของสารยับยั้งรีเวอร์สทรานสคริพเทสที่ ไม่ใช่นิวคลีโอไซด์ซึ่งมีไพริมิดีนหรือไทรอะซีนสารประกอบของการประดิษฐ์นี้ยับยั้งการติดเชื้อ ซิสเตมิคของคนโดย HIV โดยเฉพาะสารประกอบนี้ป้องกันการแพร่โดยทางเพศของ HIV ในคนDC60 (06/08/46) This invention relates to the microbial activity of a non-nucleoside reverse transcriptase inhibitor containing pyrimidine or triazine. The compound of this invention inhibits systemic human infection by HIV; specifically, this compound prevents sexual transmission of HIV in humans. This invention relates to the microbial activity of a non-nucleoside reverse transcriptase inhibitor containing pyrimidine or triazine. The compound of this invention inhibits systemic human infection by HIV; specifically, this compound prevents sexual transmission of HIV in humans.

Claims

------15/03/2562------(OCR) Page 9 of 16. R2a is cyano; aminocarbonyl; mono- or dimethylaminocarbonyl; C1-6 alkyl that may be selectively replaced by cyano, aminocarbonyl, or mono- or dimethylaminocarbonyl; C2-6 alkynyl replaced by cyano; and C2-6 alkynyl replaced by cyano; Each R2 independently is a hydroxyl, halo, C1-6 alkyl that may be selectively replaced by cyano or -C(=O)R4, C3-7 cycloalkyl, C2-6 alkynyl that may be selectively replaced by one or more halogen or cyano atoms, C2-6 alkynyl that may be selectively replaced by one. Or more halogen or cyano atoms, C1-6 alkyloxy, Cl-6 alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6 alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio-S(=O)pR4, -NH-S(=O)pR4, -C(=O)R4, -NHC(=O)H, -C(=O)NHNH2, -NHC(=O)r4, -C(=NH)R4 or radicals of the formula (chemical formula) where each A independently is N, CH, or CR4; B is NH, O, S, or NR4; P is 1 or 2; and R4 is methyl, amino, mono- or dimethylamino. Or polyhalomethyl; L is C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, each of the aforementioned aliphatic groups replaced by a phenyl which may be chosen to be replaced by the first, second, third, fourth or fifth surrogate each independently of the surrogate chosen in R2; or L is -X-R3, where R3 is a phenyl which may be chosen to be replaced by the first, second, third, fourth or fifth surrogate each independently of the surrogate chosen in R2; and X is -NR1-, -NH-NH-, -N=N-, -O-, -C(=O)-, -CHOH-, -S-, -S(=O)- or -S(=O)2-; eryl is a phenyl or a phenyl replaced by the first, second, third, fourth or fifth surrogate each independently of the surrogate chosen in R2; and X is -NR1-, -NH-NH-, -N=N-, -O-, -C(=O)-, -CHOH-, -S-, -S(=O)- or -S(=O)2-; eryl is a phenyl or a phenyl replaced by the first, second, third, fourth or fifth surrogate each independently of the surrogate chosen in R2. Independent of the representatives chosen from halo, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyloxy, cyano, nitro, polyhalo C1-6 alkyl, and polyhalo C1-6 alkyloxy, with the exception that the compound 2,4-di-p-cyanoanilino-1,3,5-triazine is excluded; page 14 of 16; 4-[[4-amino-r-chloro-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]amino]-benzonitrile; 4-[[4-amino-r-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]amino]-benzonitrile; or 4-[[4-[(2,4,6-triethylphenyl)amino]-!,3,r-triazine-2-yl]amino]benzonitrile; or N-α oxide, pharmaceutically accepted adjuvant salts, quaternary amines, or their stearic isomers.5. Use under any of the claims 1 through 4 where the compound is: 4-[[4-amino-r-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]amino]benzonitrile or 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile or 4-[[4-[(2,4,6-trimethylphenyl)amino]-!,3,r-triacin-2-yl]amino]benzonitrile or its N-oxide, pharmaceutically acceptable addition salts, quaternary amines or its stearioisomeric forms6. 7. Use under any of the claims 1 through 5 where the compound is 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimitinyl]amino]benzonitrile or its N-oxide, its pharmaceutically acceptable addition salt, or its quaternary amine. 8. Use under any of the claims 1 through 6 where transmission or infection occurs through the vagina. 9. Use under any of the claims 1 through 7 where the drug is in a topical form. 10. Use under any of the claims 1 through 8 where the drug is biologically binding to the site of application. 10. Use under any of the claims in clauses 1 through 9 where the drug is in the form of a gel, jelly, cream, paste, emulsion, dispersion, ointment, film, sponge, foam, aerosol, powder, intrauterine ring, uterine cap, patch, suppository, pessary, tablet, or mouthwash. 11. Use under any of the claims in clauses 1 through 9 where the drug is in the form of a drug-releasing delivery system. 12. 21. Use under any one of the claims in clauses 1 through 9 where the drug is in the form of a sustained-release delivery system, page 16 of 16, forming a gel, buffers are used to maintain a pH less than 5, pharmaceutically acceptable diluents, may be selected to contain humectants and may be selected to contain preservatives. 22. Pharmaceutical composition under claim 21 where buffers are used to maintain a pH in the appropriate range of 3.2 to 4.5. 23. Pharmaceutical composition under any one of the claims in clauses 21 to 22 where the compound is 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimicinyl]amino]benzonitrile ------------ Edited 27/5/2015 1. Use of a compound with formula (I), (II) or (III) where the compound with formula (I) corresponds to (chemical formula) (I) N-oxide, The pharmaceutically accepted addition salt or its steriogenic isomer, where Y is CR5 or N; A is CH, CR4, or N; n is 0, 1, 2, 3, or 4; Q is –NR1R2, or where Y is CR5, Q may also be hydrogen. R1 and R2 are independently selectable from hydrogen, hydroxya, C1-12 alkyl, C1-12 alkyloxy, C1-12 alkylcarbonyl, C1-12 alkyloxycarbonyl, aryl, amino, mono- or di(C1-12 alkyl)amino, mono- or di(C1-12 alkyl)aminocarbonyl, where each of the above-mentioned C1-12 alkyl groups may be selectable and each may be substituted with a substitute. One or two of which are independently selected from hydroxya, C1-6 alkyloxy, hydroxya C1-6 alkyloxy, carboxyl, C1-6 alkyloxycarbonyl, cyano, amino, imino, aminocarbonyl, aminocarcarnylamino, mono- or di(C1-6 alkyl)amino, aryl and Het; or R1 and R2 together may form pyrrolidinyl, piperidinyl, morpholinyl, acido or mono- or di(C1-12 alkyl)amino C1-4 alkylidine; R3 is hydrogen, aryl, C1-6 alkyl carbonyl, C1-6 alkyl, C1-6 alkyloxycarbonyl, C1-6 alkyl substituted with C1-6 alkyloxycarbonyl; and each R4 independently is hydroxyl, halo, C1-6 alkyl, C1-6 alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethyloxy, or where Y is CR5, then R4 may also substitute for a C1-6 alkyl substituted with cyano or aminocarbonyl; R5 is hydrogen or C1-4 alkyl; L is -X1-R6 or -X2-Alk-R7, where R6 and R7 are independently phenyl. Or phenyls are replaced by one, two, three, four, or five agents, each chosen independently from halo, hydroxyl, C1-6 alkyl, C1-6 alkyloxy, C1-6 alkylcarbonyl, C1-6 alkyloxycarbonyl, formil, cyano, nitro, amino, and trifluoromethyl; or when Y is CR5, then R6 and R7 may also be chosen from the phenyls replaced by. The first, second, third, fourth, or fifth substitutes are each chosen independently from amino carbonyls, trihalomethyloxy, and trihalomethyls; or, where Y is N, R6 and R7 may also be chosen from indanil, or indolil. Each of these indanils, or such indolils, may be replaced by one, two, third, fourth, or five substitutes, each chosen independently from halo, hydroxy, C1-6 alkyl, C1-6 alkyloxy, C1-6 alkyl carbonyl, C1-6 alkyloxycarbonyl, formyl, cyano, nitro, amino, and trifluoromethyls; when R6 may be chosen to be replaced by indanil or indolil, it is preferred that it be bound to the remaining molecule via a fused phenyl ring; for example, R6 is suitable to be 4-, 5-, 6-, or 7-indolil; X1 and X2 are independently different as -NR3-, -NH-NH-, -N=N-, -O-, -S-, -S(=O)-, or -S(=O)2-; Aik is a Cw alkandiyl; or where Y is CR5, L may also be chosen from C1-10 alkyl, C3-10 alkenyl, C3-10 alkynyl, C3-7 cycloalkyl, or C1-10 alkyl that is replaced by one or two independently chosen surrogates from C3-7 cycloalkyl, indanyl, indolyl, and phenyl, where phenyl, indanyl, and indolyl may be replaced by one, two, three, four, or, if possible, five surrogates that are independently different. Freely selected from halo, hydroxyl, C1-6 alkyl, C1-6 alkyloxycarbonyl, cyano, aminocarbonyl, C1-6 alkyloxycarbonyl, formyl, nitro, amino, trihalomethyl, trihalomethyloxy and C1-6 alkylcarbonyl; aryl is phenyl or phenyl replaced by one, two, three, four or five independently selected representatives from halo, C1-6 alkyl, C1-6 alkyloxy, cyano, nitro and trifluoromethyl; Het is an aliphatic or aromatic heterocyclic radical, which is an aliphatic heterocyclic radical. Selectively derived from pyrrolidinil, piperidinil, homopiperidinil, piperazinil, morpholinil, tetrahydrofuranil, and tetrahydrothienil, where each of these heterocyclic aliphatic radicals may be selectively substituted by an oxo group, and these heterocyclic aromatic radicals are selected from pyrroliil, furanil, thienil, pyridyl, pyrimidinil, pyrazinil, and pyridazinil, where each of these heterocyclic aromatic radicals may be selectively substituted by a hydroxyl group; and where the compound formula (II) corresponds to (chemical formula) (II) N-oxide, pharmaceutically accepted addition salts, quaternary amines and their isomers. Its stearic chemistry, where -b‘=b2-C(R2a)=b3-b4= represents the bivalent radical of the formula -CH=CH-C(R2a)=CH-CH= (b-1); -N=CH-C(R2a)=CH-CH= (b-2); -CH=N-C(R2a)=CH-CH= (b-3); -N=CH-C(R2a)N-CH= (b-4); -N=CH-C(R2a)=CH-N= (b-5); -CH=N-C(R2a)=N-CH= (b-6); -N=N-C(R2a)=CH-CH= (b-7); q is 0, 1, 2 or, where possible, q is 3 or 4; R1 is hydrogen, aryl, formyl, C1-6 alkyl carbonyl, C1-6 alkyl, C1-6 alkyl oxycarbonyl, C1-6 alkyl substituted with formyl, Cw alkyl carbonyl, Cj* alkyl oxycarbonyl; R2a is cyano, amino carbonyl, or mono- or di(methyl)amino carbonyl, Cw alkyl substituted with cyano, amino carbonyl or mono- or di(methyl)amino carbonyl, C2-6 alkynyl substituted with cyano, or C2-6 alkynyl substituted with cyano; Each R2 independently is a hydroxyl, halo, C1-6 alkyl that may be selectively substituted with cyano or -C(=O)R6, C3-7 cycloalkyl, C2-6 alkynyl that may be selectively substituted with one or more atoms. More than a halogen or cyano, a C2-6 alkyl oxycarbonyl, which may be selectively replaced by one or more atoms of a halogen or cyano, C1-6 alkyl oxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6 alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=O)pR6, -NH-S(=O)pR6, -C(=O)pR6, -NHC(=O)H, -C(=O)NHNH2, -NHC(=O)R6, -C(=NH)R6 or radical formula (chemical formula) (C), where each A independently is N, CH or CR6; B is NH, O, S or NR6; P is 1 or 2; and R6 is methyl, amino, mono- or dimethylamino or polyhalomethyl; L is C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, where each of these aliphatic groups may be replaced by one or two independently selected surrogates of *C3-7 cycloalkyl*, *indolyl*, or *isoindolyl*. Each aromatic ring may be chosen to be replaced by one, two, three, four, or five substitutes, each chosen independently from the halo, C1-6 alkyl, hydroxyl, C1-6 alkyloxy, cyano, aminocarbonyl, nitro, amino, polyhalomethyl, polyhalomethyloxy and C1-6 alkyl carbonyl, *phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, where each aromatic ring may be chosen to be replaced by one, two, three, four, or five substitutes, each chosen independently from the substitutes defined in R2; or L is -X-R3, where R3 is phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, where each aromatic ring... Each element may be chosen to be replaced by one, two, three, four, or five substitutes, each chosen independently of the substitutes defined in R2 and X, i.e., -NR1-, -NH-NH-, -N-N-, -O-, -C(=O)-, -CHOH-, -S-, -S(=O)-, or -S(=O)2-; Q represents hydrogen, C1-6 alkyl, halo, polyhalo C1-6 alkyl, or -NR4R5; And R4 and R5 are independently selectable from hydrogen, hydroxya, C1-12 alkyl, C1-12 alkyloxy, C1-12 alkyl carbonyl, C1-12 alkyloxycarbonyl, aryl, amino, mono- or di(C1-12 alkyl) amino, mono- or di(C1-12 alkyl) aminocarbonyl, where each of the above-mentioned C1-12 alkyl groups may be selected and each is replaced by one or two selected substitutes. Independent of hydroxya, C1-6 alkyloxy, hydroxya C1-6 alkyloxy, carboxyl, C1-6 alkyloxycarbonyl, cyano, amino, imino, mono- or di(C1-6 alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=O)pR6, -NH-S(=O)pR6, -C(=O)R6, -NHC(=O)H, -C(=O)NHNH2, -NHC(=O)R6, -C(=NH)R6, aryl and Het; Or the combination of R4 and R5 may form pyrrolidinil, piperidinil, morpholinil, acido, or mono- or di(C1-12 alkyl)amino C1-4 alkylidine; Y represents hydroxyl, halo, C3-7 cycloalkyl, C2-6 alkenyl which may be selectively replaced by one or more halogen atoms, C2-6 alkynyl which may be selectively replaced by halogen atoms. One or more atoms, C2-6 alkyls, may be selectively replaced by cyano or -C(=O)R6, C1-6 alkyl oxycarbonyl, C1-6 alkyl oxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6 alkyl)amino, polyhalomethyl, polyhalomethyl oxycarbonyl, polyhalomethyl thio, -S(=O)pR6, -NH-S(=O)pR6, -C(=O)R6, -NHC(=O)H, -C(=O)NHNH2, -NHC(=O)R6, -C(=NH)R6, or aryl. aryl is a phenyl or phenyl substituted by the first, second, third, fourth, or fifth substitute by each selective agent. Free from halo, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyloxy, cyano, nitro, polyhalo C1-6 alkyl, and polyhalo C1-6 alkyloxy; Het is an aliphatic or aromatic heterocyclic radical which is selectively chosen for pyrrolidinil, piperidinil, homopiperidinil, piperazinil, morpholinil, tetrahydrofuranil and tetrahydrothienil, where each of these aliphatic heterocyclic radicals may be selectively chosen for substitution by an oxogroup; and these aromatic heterocyclic radicals are selected. From pyrrolil, furanil, thienil, pyridinil, pyrimidinil, pyrazinil, and pyridazinil, where such aromatic heterocyclic radicals may be selectively replaced by hydroxyl radicals; Het is intended to include all possible isomeric forms of heterocyclic compounds mentioned in the definition of Het, for example, pyrrol also includes 2H-pyrrolil; the Het radical may be linked to the rest of the compound(II) molecule via the carbon of the ring or any heteroatom as appropriate, so for example, when the heterocyclic compound is pyridinil it may be 2-pyridinil, 3-pyridinil or 4-pyridinil; and where the compound(III) corresponds to (chemical formula)(III) N-oxide, pharmaceutically acceptable addition salts, quaternary amines and their isomeric forms. Its stereochemistry, where -a1=a2=a3=a4- represents the bivalent radicals of the formula -CH=CH-CH=CH- (a-1); -N=CH-CH=CH- (a-2); -N=CH-N=CH- (a-3); -N=CH-CH=N- (a-4); -N=N-CH=CH- (a-5); N is 0, 1,2,3, or 4; and in the case where -a=a2=a3=a4- is (a-1), then n could also be 5. R1 is hydrogen, aryl, formil, cb6 alkylcarbonyl, c.6 alkyl, c1-6 alkyloxycarbonyl, c.6 alkyl substituted with formil, C1-6 alkylcarbonyl, C1-6 alkyloxycarbonyl; Each R2 is independently a hydroxya, halo, C,.6 alkyl that may be selectively replaced by a cyano, or -C(=O)R4, C3.7 cycloalkyl, C2.6 alkenyl that may be selectively replaced by one or more halogen atoms, or cyano, C2.6 alkynyl that may be selectively replaced by one atom. or more of halogen or cyano, C1.6 alkyloxy, C1-6 alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1.6 alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=O)pR4, -NH-S(=O)PR4, -C(=O)R4, -NHC(=O)H, -C(=O)NHNH2, -NHC(=O)R4, -C(=NH)R4 or radical formula (chemical formula) (c) where each A independently is N, CH or CR4; B is NH, O, S or NR4; P is 1 or 2; and R4 is methyl, amino, mono- or dimethylamino or polyhalomethyl; L represents C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, where each of these aliphatic groups may be replaced by one or two independently chosen substitutes from *C3-7 cycloalkyl, *indolyl, or isoindolyl. Each substitute may be replaced by one, two, three, or four independently chosen substitutes from halo, C1-6 alkyl, hydroxyl, C1-6 alkyloxy, cyano, aminocarbonyl, nitro, amino, polyhalomethyl, polyhalomethyloxy, and C1-6 alkylcarbonyl, *phenyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl, where the aromatic ring is Each element may be chosen to be replaced by one, two, three, four, or five independent representatives from the representatives specified in R2; or L is -X-R3, where R3 is phenyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl, where each element of the aromatic ring may be chosen to be replaced by one, two, three, four, or five independent representatives from the representatives specified in R2; and X is -NR1-, -NH-NH-, -N=N-, -O-, -C(=O)-, -CHOH-, -S-, -S(=O)-, or -S(=O)2-; ERIL is phenyl or phenyl replaced by one, two, three, four, or five independent representatives from each individual choice. Free from halo, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyloxy, cyano, nitro, polyhalo C1-6 alkyl, and polyhalo C1-6 alkyloxy; with the exception that compounds with formula (III) are excluded where *L is C1-3 alkyl; R1 is chosen from hydrogen, ethyl, and methyl; -a=a2=a3=a4- represents the bivalent radical of formula (a-1); n is 0 or 1, and R2 is chosen from fluoro, chloro, methyl, trifluoromethyl, ethyloxy, and nitro; Or, * L is -X-R3, X is -NH-; R1 is hydrogen; -a=a2=a3=a4- represents the bivalent radical formula (a-1); n is 0 or 1, and R2 is chosen from chloro, methyl, methyloxy, cyano, amino, and where each A independently is N, CH or CR4; B is NH, O, S or NR4; P is 1 or 2; and R4 is methyl, amino, mono- or dimethylamino or polyhalomethyl; L is C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, where each of these aliphatic groups may be replaced by one or two independently chosen representatives from * C3-7 cycloalkyl, * indolyl or isoindolyl. Each option shall be replaced by one, two, three, or four independently selected agents from the halo, C1-6 alkyl, hydroxyl, C1-6 alkyloxy, cyano, amino carbonyl, nitro, amino, polyhalomethyl, polyhalomethyloxy and C1-6 alkyl carbonyl, *phenyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl, where each of these aromatic rings may be independently replaced by one, two, three, four, or five independently selected agents from the agents specified in R2; or L is -X-R3, where R3 is phenyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl, where each of these aromatic rings An option may be chosen to be replaced by one, two, three, four or five substitutes, each option independently of the substitutes specified in R2; and X is -NR1-, -NH-NH-, -N=N-, -O-, -C(=O)-, -CHOH-, -S-, -S(=O)- or -S(=O)2-; aryl is phenyl or phenyl replaced by one, two, three, four or five substitutes, each option independently of halo, C1-6 alkyl, C3-7 cycloalkyl, C,1-6 alkyloxy, cyano, nitro, polyhalo C1-6 alkyl, and polyhalo C1-6 alkyloxy; with the exception that compounds with formula (III) are excluded where *L is C1-3 alkyl; R1 is chosen from hydrogen, ethyl, and methyl; -a=a2=a3=a4- represents the bivalent radical of formula (a-1); n is 0 or 1, and R2 is chosen from fluoro, chloro, methyl, trifluoromethyl, ethyloxy, and nitro; or, *L is -X-R3,X is -NH-;R1 is hydrogen; -a=a2=a3=a4- represents the bivalent radical of formula (a-1); n is 0 or 1, and R2 is chosen from chloro, methyl, methyloxy, cyano, amino, and nitro, and R3 is phenyl which may be chosen to be replaced by a single substitute chosen from chloro, methyl, methyloxy, cyano, amino, and nitro; and the compound * N, N’-dipyridinyl-(1,3,5)-triazine-2,4-diamine; * (4-chloro-phenyl)-(4(1-(4-isobutyl-phenyl)-ethyl)-(1,3,5)triazine-2-yl)-amine in the production of drugs that are useful for preventing the spread of HIV or HIV infection where the spread or infection is through sexual intercourse or close contact between partners and where the compound is used at 2. Use according to claim 1, where Y in the compound formula (II) replaces hydroxyl, halo, C3-7 cycloalkyl, C2-6 alkynyl which may be selectively replaced by one or more halogen atoms, C2-6 alkynyl which may be selectively replaced by one or more halogen atoms, C1-6 alkyl which is replaced by cyano or -C(=O)R6, C1-6 alkyloxy, C1-6 alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6 alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=O)pR6, -NH-S(=O)pR6, -C(=O)R6, -NHC(=O)H, -C(=O)NHNH2, -NHC(=O)R6, -C(=NH)R6 or aryl. 3. Use according to claim 1 or 2 where the compound corresponds to (chemical formula) N-oxide, pharmaceutically acceptable addition salt, quaternary amine or its steariochemical isomer, where n is 0, 1, 2, 3 or 4; R1 is hydrogen, aryl, formyl, C1-6 alkyl carbonyl, C1-6 alkyl, C1-6 alkyl oxycarbonyl, C16 alkyl substituted for formyl, C1-6 alkyl carbonyl, C1-6 alkyl oxycarbonyl; and R2n is cyano; amino carbonyl; mono- or dimethyl amino carbonyl; C1-6 alkyl which may be selected. Substituted with cyano, aminocarbonyl, or mono- or dimethylaminocarbonyl; C2-6 alkynil substituted with cyano; and C2-6 alkynil substituted with cyano; each R2 independently is a hydroxya, halo, C1-6 alkyl that may be selectively substituted with one or more cyano atoms, or -C(=O)R4, C3-7 cycloalkyl, C2-6 alkynil that may be selectively substituted with one or more halogen or cyano atoms, C2-6 alkynil that may be selectively substituted with one or more halogen or cyano atoms, C1-6 alkyloxy, C1-6 alkyloxy. Carbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6 alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio-S(=O)pR4, -NH-S(=O)pR4, -C(=O)R4, -NHC(=O)H, -C(=O)NHNH2, -NHC(=O)R4, -C(=NH)R4 or derivative of the formula (chemical formula) (c) where each A independently is N, CH, or CR4; B is NH, O, S or NR4; P is 1 or 2; and R4 is methyl, amino, mono- or dimethylamino or polyhalomethyl; L is C1-10 alkyl, C2-10 alkenyl, C2-10 Alkinil, C3-7 cycloalkyl, each of the aforementioned aliphatic groups is replaced by a phenyl, which may be chosen to be replaced by the first, second, third, fourth, or fifth surrogate independently of the surrogate chosen in R2; or L is -X-R3, where R3 is a phenyl, which may be chosen to be replaced by the first, second, third, fourth, or fifth surrogate independently of the surrogate chosen in R2; and X is -NR1-, -NH-NH-, -N=N-, -O-, -C(=O)-, -CHOH-, -S-, -S(=O)-, or -S(=O)2-; aryl is a phenyl or a phenyl replaced by the first, second, third, fourth, or fifth surrogate independently of the surrogate chosen in R2. Independent of the representatives chosen from the halo, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyloxy, cyano, nitro, polyhalo C1-6 alkyl, and polyhalo C1-6 alkyloxy compounds, with the exception that the compound 2,4-di-p-cyanoanilino-1,3,5-triazine is excluded. 4. Use under any one of the claims of claims 1 through 3 where the compound is 4-[[4-amino-6-[(2,6-dichlorophenyl)methyl]-2-pyrimicinyl]amino]benzonitrile; 6-[(2,6-dichlorophenyl)methyl]-N2-(4-fluorophenyl)-2,4-pyrimidine diamine; 4-[[4-[(2,4-dichlorophenyl)methyl]-6-[(4-hydroxybutyl)amino]-2-pyrimidinyl]amino]-benzonitrile; * 4-[[4-[(2,6-dichlorophenyl)methyl]-6-[(3-ridoxypropyl)amino]-2-pyrimidinyl]-amino]benzonitrile; N-[2-[(4-cyanophenyl)amino]-6-[(2,6-dichlorophenyl)methyl]-4-pyrimidinyl]-acetamide; N-[2-[(4-cyanophenyl)amino]-6-[(2,6-dichlorophenyl)methyl]-4-pyrimidinyl]-butanamide; 4-[[2-amino-6-[(2,6-dichlorophenoxy)-4-pyrimidinyl]amino]benzonitrile; 4-[[4-[(2,6-dichlorophenyl)methyl]-6-[(2-hydroxy-2-phenylethyl)amino]-2-pyrimidinyl]amino] benzonitrile; 4-[[4-[(2,6-dichlorophenyl)methyl]-6-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]-2-pyrimidinyl]amino]benzonitrile; 4-[[4-[(2,6-dichlorophenyl)methyl]-6-[[2-(2-hydroxyethoxy)ethyl]amino]-2-pyrimidinyl]amino] benzonitrile monohydrochloride; 4-[[4-[(2,6-dichlorophenyl)methyl]-6-[(2,3-diroxypropyl)amino]-2-pyrimidinyl]-amino] benzonitrile; 4-[[4-[(2,6-dichlorophenyl)methyl]-6-(hydroxyamino)-2-pyrimidinyl]amino]-benzonitrile; 4-[[4-[(2-cyanoethyl)amino]-6-[(2,6-dichlorophenyl)methyl]-2-pyrimidinyl]amino]-benzonitrile; 4-[[4-[(2,6-dichlorophenyl)methyl]-6-[[2-(1-pyrrolidinyl)ethyl]amino]-2-pyrimidinyl]-amino] benzonitrile; 4-[[4-amino-6-[(2,6-dichlorophenyl)methyl]-5-methyl-2-pyrimidinyl]amino]-benzonitrile; N2-(4-bromophenyl)-6-[(2,6-dichlorophenyl)methyl]-5-methyl-2,4-pyrimidinyl diamine; 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile; 4-[[2-[(2,4,6-trimethylphenyl)amino]-4-pyrimidinyl]amino]benzonitrile; 4-[[4-[(2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile; 4-[[4-(2,4,6-trimethylphenoxy)-2-pyrimidinyl]amino]benzonitrile; 4-[[4-[(2,6-dichlorophenyl)thio]-2-pyrimidinyl]amino]benzonitrile; 4-[[4-[[2,6-dibromo-4-(1-methylethyl)phenyl]amino]-2-pyrimidinyl]amino]benzonitrile; 4-[[4-[[2,6-dichloro-4-(trifluoromethyl)phenyl]amino]-2-pyrimidinyl]amino]-benzonitrile; 4-[[4-[(2,4-dichloro-6-methylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile; 4-[[2-[(cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylbenzonitrile; 4-[[4-[(2,4-dibromo-6-fluorophenyl)amino]-2-pyrimidinyl]amino]benzonitrile; 4-[[4-amino-6-[(2,6-dichlorophenyl)methyl]-5-methyl-2-pyrimidinyl]amino]-benzeneacetonitrile; 4-[[4-[methyl(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile; 4-[[4-[(2,4,6-trichlorophenyl)amino]-2-pyrimidinyl]amino]benzonitrile; 4-[[4-[(2,4,6-trimethylphenyl)thio]-2-pyrimidinyl]amino]benzonitrile; 4-[[4-[(2,4,6-trimethylphenyl)amino-2-pyrimidinyl]amino]benzonitrile; 4-[[4-amino-6-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile; 4-[[2-amino-6-[(2,4,6-trimethylphenyl)amino]-4-pyrimidinyl]amino]benzonitrile; 4-[[4-(2-bromo-4-chloro-6-methylphenoxy)-2-pyrimidinyl]amino]benzonitrile; 4-[[4-[(4-chloro-2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile; 3,5-dichloro-4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]benzonitrile; 4-[[4-[[2,6-dichloro-4-(trifluoromethoxy)phenyl]amino]-2-pyrimidinyl]amino]-benzonitrile; 4-[[4-[(2,4-dibromo-3,6-dichlorophenyl)amino]-2-pyrimidinyl]amino]benzonitrile; 4-[[4-[(2,6-dibromo-4-propylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile; 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzamide; 4-[[4-[(4-(1,1-dimethylethyl)-2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]-benzonitrile; 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethylbenzonitrile; 4-[[4-[(4-chloro-2,6-dimethylphenyl)amino]-5-methyl-2-pyrimidinyl]amino]-benzonitrile; 4-[[2-[(4-cyanophenyl)amino]-5-methyl-4-pyrimidinyl]amino]-3,5-dimethylbenzonitrile; 4-[[4-[[4-(1,1-dimethylethyl)-2,6-dimethylphenyl]amino]-5-methyl-2-pyrimidinyl]-amino]benzonitrile; 4-[[4-[(4-bromo-2,6-dimethylphenyl)amino]-5-methyl-2-pyrimidinyl]amino]-benzonitrile; 4-[[5-methyl-4-[(2,4,6-trimethylphenyl)thio]-2-pyrimidinyl]amino]benzonitrile; 4-[[4-[(2,6-dibromo-4-propylphenyl)amino]-5-methyl-2-pyrimidinyl]amino]-benzonitrile; 4-[[4-[(2,4,6-trimethylphenyl)amino]-2•pyrimidinyl]amino]benzamide,N3-oxide; N2-(4-chlorophenyl)-N4-(2,4,6-trimethylphenyl)-2,4-pyrimidine diamine; 4-[[4-[[2,6-dibromo-4-(1-methylethyl)phenyl]amino]-5-methyl-2-pyrimidinyl]amino]-benzonitrile; 4-[[2-[(4-cyanophenyl)lamino]-5-methyl-4-pyrimidinyl]amino]-3,5-dimethylbenzonitrile; 4-[[4-[(phenylmethyl)amino]-2-pyrimidinyl]amino]benzonitrile; 4-[[4-amino-6-(2,6-dimethylphenoxy)-!,3,5-triazine-2-il]amino]benzonitrile; 4-[[4-amino-6-[(2-chloro-6-methylphenyl)amino]-1,3,5-triazine-2-il]amino]benzonitrile; 4-[[4-amino-6-[(2,4,6-trimethylphenyl)amino]-1,3,5-triazine-2-il]amino]benzonitrile; 4-[[4-(hydroxyamino)-6-[(2,4,6-trimethylphenyl)amino]-1,3,5-triazine-2-il]amino]-benzonitrile; 4-[[4-amino-6-[(2-ethyl-6-methylphenyl)amino]-1,3,5-triazine-2-il]amino]benzonitrile; 4-[[4-amino-6-[(2,6-dichlorophenyl)thio]-1,3,5-triazine-2-il]amino]benzonitrile; 4-[[4-(hydroxyamino)-6-[(2,4,6-trichlorophenyl)amino]-1,3,5-triazine-2-il]amino]-benzonitrile; 4-[[4-amino-6-(2,4,6-trimethylphenoxy)-1,3,5-triazine-2-il]amino]benzonitrile; 4-[[4-(hydroxyamino)-6-(2,4,6-trimethylphenoxy)-1,3,5-triazine-2-il]amino]-benzonitrile; 4-[[4-amino-6-[(2,4-dichloro-6-methylphenyl)amino]-1,3,5-triazine-2-il]amino]-benzonitrile; 4-[[4-[(2,4-dichloro-6-methylphenyl)amino]-6-(hydroxyamino)-1,3,5-triazine-2-il]-amino] benzonitrile; 4-[[4-(hydroxyamino)-6-[(2,4,6-trichlorophenoxy)-1,3,5-triazine-2-il]amino]benzonitrile trifluoroacetate (1:1); 4-[[4-(4-acetyl-2,6-dimethylphenoxy)-6-amino-1,3,5-triazine-2-il]amino]benzonitrile; 4-[[4-amino-6-(2,4,6-tribromophenoxy)-1,3,5-triazine-2-il]amino]benzonitrile; 4-[[4-amino-6-(4-nitro-2,6-dimethylphenoxy)-1,3,5-triazine-2-il]amino]benzonitrile; 4-[[4-amino-6-(2,6-dibromo-4-methylphenoxy)-1,3,5-triazine-2-il]amino]benzonitrile; 4-[[4-amino-6-(4-formyl-2,6-dimethylphenoxy)-1,3,5-triazine-2-il]amino]benzonitrile; 4-[[4-amino-6-[(2,4-dichlorophenyl)thio]-1,3,5-triazine-2-il]amino]benzonitrile; 4-[[4-[(5-acetyl-2,3-dihydro-7-methyl-IH-inden-4-il)oxy)-6-amino-1,3,5-triazine-2-il]-amino]benzonitrile; 4-[[4-amino-6-[(4-bromo-2-chloro-6-methylphenyl)amino]-1,3,5-triazine-2-il]amino]-benzonitrile; 4-[[4-amino-6-[(2-chloro-4,6-dimethylphenyl)amino]-1,3,5-triazine-2-il]amino]-benzonitrile; 4-[[4-amino-6-[[2,4-dichloro-6-(trifluoromethyl)phenyl]amino]-1,3,5-triazine-2-il]-amino] benzonitrile; 4-[[4-amino-6-[methyl(2,4,6-trimethylphenyl)amino]-1,3,5-triacin-2-il]amino]-benzo nitrile; 4-[[4-amino-6-[(2,6-dibromo-4-methylphenyl)amino]-1,3,5-triacin-2-il]amino]-benzo nitrile; 4-[[4-amino-6-[[2,6-dibromo-4-(1-methylethyl)phenyl]amino]-1,3,5-triacin-2-il]-amino]benzo nitrile; 4-[[4-amino-5-chloro-6-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]-benzonitrile; 4-[[5-chloro-4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile; 4-[[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]amino]benzonitrile; 4-[[4-amino-5-chloro-6-[(4-cyano-2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]-benzonitrile; 4-[[5-bromo-6-[(4-cyano-2,6-dimethylphenyl)amino]-2-pyrimidinil]amino]benzonitrile; 4-[[4-amino-5-chloro-6-(4-cyano-2,6-chimethylphenyloxy)-2-pyrimidinil]amino]-benzonitrile; 4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinil]amino]-benzonitrile ; or 4-[[4-[(2,4,6-trimethylphenyl)amino]-1,3,5-triazine-2-yl]amino]benzonitrile; or N-oxide, pharmaceutically acceptable addition salt, quaternary amine or its stearic isomer. 5. Use under any of the claims 1 through 4 where the constituent is 4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]amino]benzonitrile or 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile or 4-[[4-[(2,4,6-triazine-2-yl]amino]benzonitrile 6. Use under any of the claims 1 through 5 where the compound is 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile or its N-oxide, its pharmaceutically acceptable addition salt, its quaternary amine or its stearioisomeric form. 7. Use under any of the claims 1 through 6 where the transmission or infection is 8. Use under any one of the claims in clauses 1 through 7 where the drug is in a topical form. 9. Use under any one of the claims in clauses 1 through 8 where the drug is biologically binding to the site of application. 10. Use under any one of the claims in clauses 1 through 9 where the drug is in the form of a gel, jelly, cream, paste, emulsion, dispersion, ointment, film, sponge, foam, aerosol, powder, intravaginal ring, uterine cap, implant, patch, suppository, pessary, tablet, or mouthwash. 11. Use under any one of the claims in clauses 1 through 9 where the drug is in the form of an immediate-release delivery system. 12. Use under any one of the claims in clauses 1 through 9 where the drug is in the form of a sustained-release delivery system. 13. Use under any one of the claims in clauses 1 through 12 where the drug is a gel consisting of... Contains the effective antimicrobial concentrations of the compounds as specified in Claim 1, and pharmaceutically acceptable gelling, buffering, and diluting compounds. May be enhanced with humectants and may be enhanced with preservatives. 14. Use under any one of the claims in clauses 1 through 13 where the drug contains 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-primidinyl]amino]benzonitrile, hydroxyethyl cellulose, glycerol, methylparaben, propylparaben, lactic acid, sodium hydroxide and water. 15. Use under any one of the claims in clauses 1 through 14 where the drug contains one or more antiretroviral compounds. 16. Use under any one of the claims in clauses 1 through 15 where the drug contains additional compounds. 17. A pharmaceutical composition containing one or more components selected from antibodies, detergents, or surfactants; a coating for pathogens; a coating for the transmission site; an antibiotic peptide; or a pH regulator. 18. A use under any of the claims in clauses 1 through 6 where the drug is additionally contained with a spermicidal compound. 19. A use under any of the claims in clauses 1 through 6 where the drug is useful for the prevention of Haemophilus ducreyi transmission. 20. A pharmaceutical composition containing a pharmaceutically accepted carrier and, as the active ingredient, in an amount that provides the microbial effect of any of the compounds mentioned in claims 1 through 6, where the pharmaceutical composition is in the form of an intravaginal ring or intrauterine cap. 21. A pharmaceutical composition containing a pharmaceutically accepted carrier and, as the active ingredient, in an amount that provides the microbial effect of any of the compounds mentioned in claims 1 through 6. The amount of antimicrobial activity of any of the compounds mentioned in claims 1 through 6, where the composition is a gel containing the amount of antimicrobial activity of any of the compounds specified in claims 1 through 6, the gel-forming compound, a buffer used to maintain a pH less than 5, a pharmaceutically acceptable diluent, a humectant may be selected, and a preservative may be selected. 22. A pharmaceutical composition according to claim 21 where the buffer is used to maintain a pH in the range of approximately 3.2 to approximately 4.5. 23. A pharmaceutical composition according to any of claims 21 through 22 where the compound is 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile. 24. A method of prevention of HIV transmission or infection consisting of the administration of an individual to any of the compounds specified in claims 1 through 6. Where transmission or infection occurs through sexual intercourse or close contact between partners, and where compounds are applied to areas of sexual intercourse or close contact between partners.

1. Use of compounds with mixed formulas (I), (II), and (III), where the compound of formula (I) corresponds to (formula) (I) N-oxide, a pharmaceutically acceptable acid-additive salt or its steariochemical isomer, where Y is CR5 or N; A is CH,CR4, or N; n is 0,1,2,3, or 4; Q is -NR1R2 or where Y is CR5, then Q may also be hydrogen; R1 and R2 are independently selected from hydrogen, hydroxya, C1-12 alkyl, C1-12 alkyloxy, C1-12 alkylcarbonyl, C1-12 alkyloxycarbonyl, aryl, amino, mono- or (C1-12 alkyl)amino, mono- or (C1-12 alkyl)aminocarbonyl, where the C1-12 alkyl group but The aforementioned compounds may be selected, and each may be replaced by one or two substituents chosen independently of hydroxyl, C1-C6 alkyloxy, hydroxyl C1-C6 alkyloxy, carboxyl, C1-C6 alkyloxycarbonyl, cyano, amino, imino, aminocarbonyl, aminocarbonylamino, mono- or di(C1-C6 alkyl)amino, aryl and Her; or R1 and R2 together may form pyrrolidinyl, piperidinyl, morpholidinyl, acido or mono- or di(C1-12 alkyl)amino C1-C4 alkylidine; R3 is hydrogen, aryl, C1-C6 alkyl carbonyl, C1-C6 alkyl, C1-C6 alkyloxycarbonyl, C1-C6 alkyl substituted by C1-C6 alkyloxycarbonyl; and each R4 independently is hydroxyl, halo, C1-C6 alkyl, C1-C6 alkyloxy, cyano, amino carbonyl, nitrile, amino, trihalomethyl, trihalomethyloxy, or where Y is CR5, then R4 may be substituted by a C1-C6 alkyl substituted by a cyano or amino carbonyl as well; R5 is hydrogen or C1-C4 alkyl; L is -X1-R6 or -X2-Alk-R7, where R6 and R7 independently are phenyl. Or phenyls replaced by one, two, three, four, or five substitutions each independently of halo, hydroxy, C1-C6 alkyl, C1-C6 alkyloxy, C1-C6 alkylcarbonyl, C1-C6 alkyloxycarbonyl, formil, cyano, nitro, amino, and trifluoromethyl; or when Y is CR5, then R6 and R7 may also be chosen from phenyls replaced by one, two, three, four, or five substitutions each independently of amino carbonyl, trihalomethyloxy, and trihalomethyl; or when Y is N, then R6 and R7 may also be chosen from indanyl, or individual indolyls of indanyl, or such indolyls. It can be replaced by one, two, three, four, or five parts, each option independently of halo, hydroxyl, C1-C6 alkyl, C1-C6 alkyloxy, C1-C6 alkylcarbonyl, C1-C6 alkyloxycarbonyl, formil, cyano, nitro, amino, and trifluoromethyl; when R6 is chosen to replace indanil or indolyl, it should be coupled to the remaining molecule by a fused phenyl ring, for example, R6 is suitable to be 4-, 5-, 6-, or 7-indolyl; X1 and X2 are independently -NR3-, -NH-NH-, -N=N-, -O-, -S-, -S(=O)-, or -S(=O)2-; Alk is C1-4 alkandiyl; Or, where Y is CR5, L may be chosen from C1-10 alkyls, C3-10 alkenyls, C3-10 alkynyls, C3-7 cycloalkyls, or C1-10 alkyls replaced by one or two independently selected substituents from C3-7 cycloalkyls, indanyls, indolyls, and phenyls, where phenyls, indanyls, and indolyls may be replaced by one, two, three, four, or five independently selected possible substituents from halohydroxy C1-6 alkyls, C1-6 alkyloxycyanoaminocarbonyls, C1-6 alkyloxycarbonyl formyls, nitroaminotrihalomethyls, and C1-6 alkylcarbonyls; ERIL is phenyl, or phenyl substituted by one, two, three, four, or five substituents, each independently selected from halo C1-6, alkyl C1-6, alkyloxycyano, nitro, and trifluoromethyl; Het is an aliphatic or aromatic heterocyclic radical. Such aliphatic heterocyclic radicals are selective for pyrrolidinil, piperidinil, homopiperidinil, piperazinil, morpholinil, tetrahydrofuranil, and tetrahydrothienil, each of which may be selectively substituted by an oxogroup, and aromatic heterocyclic radicals. Such cyclic radicals are selectively chosen from pyrrolyl, furanil, thienil, pyridyl, pyrimidinil, pyrazinil, and pyridazinil, where such heterocyclic aromatic radicals may be selectively substituted by hydroxyl radicals; and where the compounds of the formula (II) are corresponding to (formula) (II) N-oxide, the pharmaceutically acceptable added salts, quaternary amines, and their stearoidal isomers, where -b1=b2-C(R2a)=b3-b4= represent the bivalent radicals of the formula. -CH=CH-C(R2a)=CH-CH= (b-1); -N=CH-C(R2a)=CH-CH= (b-2); -CH=N-C(R2a)=CH-CH= (b-3); -N=CH-C(R2a)=N-CH= (b-4); -N=CH-C(R2a)=CH-N= (b-5); -CH=N-C(R2a)=N-CH= (b-6); -N=N-C(R2a)=CH-CH= (b-7); q is 0, 1, 2 or, where possible, q is 3 or 4; R1 is hydrogen aryl formyl C1-6 alkyl carbonyl C1-6 alkyl C1-6 alkyl oxycarbonyl C1-6 akyl substituted by formyl C1-6 alkyl carbonyl C1-6 Alkyloxycarbonyl; R2a is a cyanoaminocarbonyl mono- or di(methyl)aminocarbonyl C1-6 alkyl substituted with a cyanoaminocarbonyl mono- or di(methyl)aminocarbonyl or C2-6 alkenyl substituted with a cyano or C2-6 alkynyl substituted with a cyano; each R2 independently is a hydroxyhalo C1-6 alkyl selectively substituted with a cyano or -C(=O)R6, C3-7 cycloalkyl C2-6 alkenyl selectively substituted with one or more halogen atoms or cyano C2-6 alkynyl selectively substituted with one or more halogen atoms or cyano C1-6 alkyloxyC1-6. Alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or dimethyl (C1-6) alkyl) amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio -S(=O)pR6, -NH-S(=O)pR6, -C(=O)R6,-NHC(=O)H, -C(=O)NHNH2, -NHC(=O)R6, -C(=NH)R6 or radicals of a mixture (formula) (c) where each A independently is N,CH or CR6; B is NH,O,S or NR6; p is 1 or 2; and R6 is methyl, amino, mono- or dimethylamino or polyhalomethyl; L represents C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, and C3-7 cycloalkyl, where each of these aliphatic groups may be replaced by one or two independently selected substituents of *C3-7 cycloalkyl, *indolyl, or isoindolyl. Each aromatic ring may be replaced by one, two, three, four, or five substitutions, each chosen independently from the substitutions defined in R2; or L is -X-R3, where R3 is phenyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl, where each aromatic ring may be replaced by one, two, three, four, or five substitutions, each chosen independently from the substitutions defined in R2; or L is -X-R3, where R3 is phenyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl, each aromatic ring may be replaced by one, two, three, four, or five substitutions, each chosen independently from the substitutions defined in R2. They are independently selected from the substituents defined in R2 and X, namely -NR1-, -NH-NH-, -N=N, -O-, -C(=O)-, -CHOH-, -S-,-S(=O)-, or -S(=O)2-; Q represents hydrogen C1-6 alkyl halo, polyhalo C1-6 alkyl, or -NR4R5; and R4 and R5 are independently selected from hydrogen hydroxyl C1-12 alkyl, C1-12 alkyloxy, C1-12 alkyl carbonyl, C1-12 alkyloxycarbonyl aryl amino mono-, or di(C1-12 alkyl)amino mono-, or di(C1-12 alkyl)aminocarbonyl, where each of the C1-12 alkyl groups mentioned above may be selected. Each is replaced by one or two substituents chosen independently of the hydroxyl C1-6 alkyloxycarbonyl, C1-6 alkyloxycarbonyl, cyano-amino-imino-mono- or di(C1-6 alkyl)amino, polyhalomethyl, polyhalomethoxy, polyhalomethylthio-S(=O)pR6, -NH-S(=O)pS6, -C(=O)R6, -NHC(=O)H, -C(=O)NHNH2, -NHC(=O)R6, -C(=NH)R6, aryl and Het; Or R4 and R5 combined may form pyrrolidinyl, piperidinyl, morpholinyl, acido, or mono- or di(C1-12 alkyl)amino, C1-4 alkylidine; Y represents hydroxyhalo, C3-7 cycloalkyl, C2-6 alkinyl may be selectively substituted with one or more halogen atoms, C2-6 alkynyl may be selectively substituted with one or more halogen atoms, C1-6 alkyl may be selectively substituted with cyano or -C(=O)R6, C1-6 alkyl oxy, C1-6 alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6 alkyl)amino, polyhalomethyl, polyhalomethyloxy. Polyhalomethylthio-S(=O)pR6, -NH-S(=O)pR6, -C(=O)R6, -NHC(=O)H, -C(=O)NHNH2, -NHC(=O)R6, -C(=NH)R6, or aryl. aryl is phenyl or phenyl substituted by one, two, three, four, or five substitutions, each chosen independently of halo, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyloxy, cyano, nitro, polyhaloC1-6 alkyl, and polyhaloC1-6 alkyloxy; Het is aliphatic or aromatic heterocyclic radical. Such aliphatic heterocyclic radicals. These aliphatic heterocyclic radicals are selectively chosen from pyrrolidinil, piperidinil, homopiperidinil, piperazinil, morpholinil, tetrahydrofuranil, and tetrahydrothienil, where each of these aliphatic heterocyclic radicals may be selectively substituted by oxide groups; and these aromatic heterocyclic radicals are selectively chosen from pyrroliil, furanil, thienil, pyridinil, pyrimidinil, pyrazinil, and pyridazinil, where these aromatic heterocyclic radicals are selectively substituted by hydroxyl groups. Het aims to integrate the forms. All possible isomers of heterocycles mentioned in the definition of Het are included, for example, pyrrol also includes 2H-pyrrol. The Het radical may be linked to the rest of the compound molecule (II) by any of the ring atoms or heterotoms as appropriate, thus, for example, when the heterocycle is pyridinyl, it may be 2-pyridinyl, 3-pyridinyl or 4-pyridinyl; and where the compounds of compound (III) correspond to (formula) (III) N-oxide, the pharmaceutically recognized added salts, quaternary amines and their stearic isomers, where -a1=a2=a3=a4- represents the bivalent radicals of compound. -CH=CH-CH=CH- (a-1); -N=CH-CH=CH- (a-2); -N=CH-N=CH- (a-3); -N=CH-CH=N- (a-4); -N=N-CH=CH- (a-5); n is 0, 1, 2, 3, or 4; and in the case -a1=a2=a3=a4- is (a-1), then n could also be 5. R1 is hydrogen, aryl, formil, C1-6 alkylcarbonyl, C1-6 alkyl, C1-6 alkyloxycarbonyl, C1-6 alkyl substituted by formil, C1-6 alkylcarbonyl, C1-6 alkyloxycarbonyl; Each R2 is independently a hydroxya, halo, C1-6 alkyl, which may be selectively replaced by a cyano or -C(=O) R4, C3-7 cycloalkyl, C2-6 alkenyl, which may be selectively replaced by one or more atoms of a halogen or cyano, C2-6 alkynyl, which may be selectively replaced by one or more atoms of a halogen or cyano, C1-6 alkyloxy, C1-6 alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6 alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=O)pR4, -NH-S(=O)pR4, -C(=O)R4, -NHC(=O)H. -C(=O)NHNH2, -NHC(=O)R4, -C(=NH)R4 or radicals of the compound formula, chemical formula (c) where each A independently is N,CH or CR4; B is NH,O,S or NR4; p is 1 or 2; and R4 is methyl, amino, mono- or dimethylamino or polyhalomethyl; L is C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, where each of the above aliphatic groups may be replaced by one or two independently selected substituents of *C3-7 cycloalkyl*, indolyl or isoindolyl. Each aromatic ring may be replaced by one, two, three, or four independently selected substituents from the halo, C1-6 alkyl, hydroxyl, C1-6 alkyloxy, cyano, amino carbonyl, nitro, amino, polyhalomethyl, polyhalomethyloxy and C1-6 alkyl carbonyl, *phenyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl, where each of these aromatic rings may be replaced by one, two, three, four, or five independently selected substituents from the substituents specified in R2; or L is -X-R3, where R3 is phenyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl, where each of these aromatic rings may be replaced by one, two, three, or five independently selected substituents from the substituents specified in R2; or L is -X-R3, where R3 is phenyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl, where each of these aromatic rings may be replaced by one, two, three, or five independently selected substituents. Selected independently from substitutions specified in R2; and X is -NR1-, -NH-NH-, -N=N-, -O-, -C(=O)-, -CHOH-, -S-,-S(=O)- or -S(=O)2-; aryl is phenyl or phenyl substituted by one, two, three or five substitutions independently selected from halo, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyloxy, cyano, nitro, polyhaloC1-6 alkyl, and polyhaloC1-6 alkyloxy; provided that the compounds of formula (III) where *L is C1-3 alkyl; R1 is selected from hydrogen, ethyl and methyl; -a1=a2=a3=a4- represents the bivalent radicals of the mixture (a-1); n is 0 or 1, and R2 is chosen from fluoro, chloro, methyl, trifluoromethyl, ethyloxy, nitro; or, *L is -X-R3, X is -NH-; R1 is hydrogen; -a1=a2=a3=4- represents the bivalent radicals of the mixture (a-1); n is 0 or 1, and R2 is chosen from chloro, methyl, methyloxy, cyano, amino, and nitro, and R3 is phenyl, which may be replaced by one substitution chosen from chloro, methyl, methyloxy, cyano, amino, and nitro; And the compounds *N,N'-dipyridinyl-(1,3,5)-triazine-2,4-diamine; *(4-chloro-phenyl)-(4(1-(4-isobutyl-phenyl)-ethyl)-(1,3,5,)triazine-2-yl)-amine are not included; in the production of drugs that are useful for preventing the spread of or infection with HIV.

2. Use of compounds of formulation (I), (II) or (III) under claim 1 in the manufacture of an antimicrobial drug for the prevention of transmission or infection of HIV, where Y in compound of formulation (II) replaces the hydroxyl, halo, C3-7 cycloalkyl, C2-6 alkenyl which may be selectively replaced by an atom. One or more halogen atoms, C2-6 alkyls that may be selectively replaced by one or more halogen atoms, C1-6 alkyls that are replaced by cyano or -C(=O)R6, C1-6 alkyloxy, C1-6 alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6 alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=O)pR6, -NH-S(=O)pR6, -C(=O)R6, -NHC(=O)H, -C(=O)NHNH2, -NHC(=O)R6,-C(=NH)R6 or aryl.

3. Uses under claim 1 or 2 where the corresponding compound (chemical formula) N-oxide, pharmaceutically acceptable addition salts, quaternary amines and their stearoidal isomers, where n is 0, 1, 2, 3 or 4; R1 is hydrogen, aryl, formyl, C1-6 alkyl carbonyl, C1-6 alkyl, C1-6 alkyl oxycarbonyl, C1-6 alkyl substituted with formyl, C1-6 alkyl carbonyl, C1-6 alkyl oxycarbonyl; and R2n is cyano; amino carbonyl; mono- or dimethyl amino carbonyl; C1-6 alkyl which may be selectively substituted with cyano, amino carbonyl, or mono- or dimethyl amino carbonyl; C2-6 alkenyl substituted with cyano; and C2-6 alkinil replaced by cyano; Each R2 is independently a hydroxya, halo, C1-6 alkyl selectively substituted with a cyano or -C(=O) atom. R4, C3-7 cycloalkyl, C2-6 alkenyl which may be selectively substituted with a halogen or cyano atom, or one or more atoms, C2-6 alkynyl selectively substituted with one or more halogen or cyano atoms. C1-6 alkyloxy, Cc1-6 alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6 alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio -S(=O)pR4, -NH-S(=O)pR4, -C(=O)R4, -NHC(=O)H, -C (=O)NHNH2, -NHC(=O)R4, -C(=NH)R4 or radicals of the compound formula (chemical formula) (c) where each A independently is N, CH or CR4; B is NH,O,S or NR4; p is 1 or 2; and R4 is methyl, amino, mono- or dimethylamino or polyhalomethyl; L is C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, each of the aliphatic groups is replaced by a phenyl which may be replaced by one, two, three, four or five substituents each chosen independently of the substituents specified in R2; or L is -X-R3 where R3 is a phenyl which may be replaced by one, two, three, four or five substituents each chosen independently of the substituents specified in R2; X is -NR1-,-NH-NH-, -N=N-, -O-, -C(=O)-, -CHOH-, -S-, -S(=O)-, or -S(=O)2-; aryl is femyl or phenyl substituted by one, two, three, four, or five substituents, each chosen independently from substituents selected from halo, C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkyl oxy, cyano, nitro, polyhalo C1-6 alkyl, and polyhalo C1-6 alkyl oxy, excluding 2,4-di-p-cyanoanilo-1,3,5-triazine.

4. Use under any one of the claims of claims 1 through 3, where the compound is 4-[[4-amino-6-[(2,6-dichlorophenyl)methyl]-2-pyrimidinyl]amino]benzonitrile; 6-[(2,6-dichlorophenyl)methyl]-N2-(4-fluorophenyl)-2,4-pyrimidine diamine; 4-[[4-[(2,4-dichlorophenyl)methyl]-6-[(4-hydroxybutyl)amino]-2-pyrimidinyl]amino]-benzonitrile; 4-[[4-[(2,6-dichlorophenyl)methyl]-6-[(3-hydroxypropyl)amino]-2-pyrimidinyl]-amino]benzonitrile; N-[2-[(4-cyanophenyl)amino]-6-[(2,6-dichlorophenyl)methyl]-4-pyrimidinyl]-acetamide; N-[2-[(4-cyanophenyl)amino]-6-[(2,6-dichlorophenyl)methyl]-4-pyrimidinyl]-butanamide; 4-[[2-amino-6-[(2,6-dichlorophenoxy)-4-pyrimidinyl]benzonitrile; 4-[[4-[(2,6-dichlorophenyl)methyl]-6-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino-2-pyrimidinyl]amino]benzonitrile; 4-[[4-[(2,6-dichlorophenyl)methyl]-6-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino-2-pyrimidinyl]amino]benzonitrile; 4-[[4-[(2,6-dichlorophenyl)methyl]-6-[[2-(2-hydroxyethoxy)ethyl]amino]-2-pyrimidinyl]amino]benzonitrile monohydrochloride; 4-[[4-[(2,6-dichlorophenyl)methyl]-6-[(2,3-dihydroxypropyl)amino]-2-pyrimidinyl]-amino] benzonitrile; 4-[[4-[(2,6-dichlorophenyl)methyl]-6-(hydroxyamino)-2-pyrimidinyl]amino]-benzonitrile; 4-[[4-[(2-cyanoethyl)amino]-6-[(2,6-dichlorophenyl)methyl]-2-pyrimidinyl]amino]-benzonitrile; 4-[[4-[(2,6-dichlorophenyl)methyl]-6-[[2-(1-pyrrolidinyl)ethyl]amino]-2-pyrimidinyl]-amino] benzonitrile; 4-[[4-amino-6-[(2,6-dichlorophenyl)methyl]-5-methyl-2-pyrimidinyl]amino]-benzonitrile; N2-(4-bromophenyl)-6-[(2,6-dichlorophenyl)methyl]-5-methyl-2,4-pyrimidine diamine; 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]imino]benzonitrile; 4-[[4-[(2,4,6-trimethylphenyl)amino]-4-pyrimidinyl]amino]benzonitrile; 4-[[4-[(2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile; 4-[[4-[(2,4,6-trimethylphenoxy)-2-pyrimidinyl]amino]benzonitrile; 4-[[4-[(2,6-dichlorophenyl)thio]-2-pyrimidinyl]amino]benzonitrile; 4-[[4-[[2,6-dibromo-4-(1-methylethyl)phenyl]amino]-2-pyrimidinyl]amino]benzonitrile; 4-[[4-[[2,6-dichloro-4-(trifluoromethyl)phenyl]amino]-2-pyrimidinyl]amino]-benzonitrile; 4-[[4-[[2,4-dichloro-6-(1-methylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile; 4-[[2-[(cyanophenyl)amino]-4-pyrimidinyl]amino]3-,5-dimethylbenzonitrile; 4-[[4-[(2,4-dibromo-6-fluorophenyl)amino]-2-pyrimidinyl]amino]benzonitrile; 4-[[4-amino-6-[(2,6-dichlorophenyl)methyl]-5-methyl-2-pyrimidinyl]amino]-benzoneacetonitrile; 4-[[4-[methyl(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzoneitrile; 4-[[4-[(2,4,6-trichlorophenyl)amino]-2-pyrimidinyl]amino]benzoneitrile; 4-[[4-[(2,4,6-trichlorophenyl)thio]-2-pyrimidinyl]amino]benzoneitrile; 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile; 4-[[4-amino-6-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile; 4-[[2-amino-6-[(2,4,6-trimethylphenyl)amino]-4-pyrimidinyl]amino]benzonitrile; 4-[[4-(2-bromo-4-chloro-6-methylphenoxy)-2-pyrimidinyl]amino]benzonitrile; 4-[[4-[(4-chloro-2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile; 3,5-dichloro-4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]benzonitrile; 4-[[4-[[2,6-dichloro-4-(trifluoromethoxy)phenyl]amino]-2-pyrimidinyl]amino]-benzonitrile; 4[[4-[(2,4-dibromo-3,6-dichlorophenyl)amino]-2-pyrimidinyl]amino]benzonitrile; 4[[4-[(2,6-dibromo-4-propylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile; 4[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzamide; 4[[4-[(4-(1,1-dimethylethyl)-2,6-dimethylphenyl)aminol-2-pyrimidinyl]amino]-benzonitrile; 4[[4-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethylbenzonitrile; 4[[4-[(4-chloro-2,6-dimethylphenyl)amino]-5-methyl-2-pyrimidinyl]amino]-benzonitrile; 4[[2-[(4-cyanophenyl)amino]-5-methyl-4-pyrimidinyl]amino]-3,5-dimethylbenzonitrile; 4-[[4-[[4-(1,1-dimethylethyl)-2,6-dimethylphenyl]amino]-5-methyl-2-pyrimidinyl]-amino]benzonitrile; 4[[2-[(4-bromo-2,6-dimethylphenyl)amino]-5-methyl-2-pyrimidinyl]amino]-benzonitrile; 4-[[5-methyl-4-[(2,4,6-trimethylphenyl)thio]-2-pyrimidinyl]amino]benzonitrile; 4-[[4-[(2,6-dibromo-4-propylphenyl)amino]-5-methyl-2-pyrimidinyl]amino]-benzonitrile; 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzamide, N3-oxide; N2-(4-chlorophenyl)-N4-(2,4,6-trimethylphenyl)-2,4-pyrimidine diamine; 4-[[4-[[2,6-dibromo-4-(1-methylethyl)phenyl]amino]-5-methyl-2-pyrimidinyl]amino]-benzonitrile; 4-[[2-[(4-cyanophenyl)amino]-5-methyl-4-pyrimidinyl]amino]-3,5-dimethylbenzonitrile; 4-[[4-[(phenylmethyl)amino]-2-pyrimidinyl]amino]benzonitrile; 4-[[4-amino-6-(2,6-dimethylphenoxy)-1,3,5-triazine-2-yl]amino]benzonitrile; 4-[[4-amino-6-[(2-chloro-6-methylphenyl)amino]-1,3,5-triazine-2-il]amino]benzonitrile; 4-[[4-amino-6-[(2,4,6-trimethylphenyl)amino]-1,3,5-triazine-2-il]amino]benzonitrile; 4-[[4-(hydroxyamino)-6-[(2,4,6-trimethylphenyl)amino]-1,3,5-triazine-2-il]amino]benzonitrile; 4-[[4-amino-6-[(2-ethyl-6-methylphenyl)amino]-1,3,5-triazine-2-il]amino]benzonitrile; 4-[[4-amino-6-[(2,6-ethyl-6-dichlorophenyl)-1,3,5-triazine-2-il]amino]benzonitrile; 4-[[4-(hydroxyamino)-6-[(2,4,6-trichlorophenyl)amino]-1,3,5-triazine-2-il]amino]-benzonitrile; 4-[[4-amino-6-(2,4,6-trimethylphenoxy)-1,3,5-triazine-2-il]amino]benzonitrile; 4-[[4-(hydroxyamino)-6-(2,4,6-trimethylphenoxy)-1,3,5-triazine-2-il]amino]-benzonitrile; 4-[[4-amino-6-[(2,4,-dichloro-6-methylphenyl)amino]-1,3,5-triazine-2-il]amino]benzonitrile; 4-[[4-[(2,4-dichloro-6-methylphenoxy)amino]-6-(hydroxyamino)-1,3,5-triazine-2-il]-amino] benzonitrile; 4-[[4-(hydroxyamino)-6-[(2,4,6-trichlorophenoxy)-1,3,5-triazine-2-il]amino]benzonitrile trifluoroacetate (1:1); 4-[[4-(4-acetyl-2,6-dimethylphenoxy)-6-amino-1,3,5-triazine-2-il]aminol benzonitrile; 4-[[4-amino-6-(2,4,6-tribromophenoxy)-1,3,5-triazine-2-il]amino]benzonitrile; 4-[[4-amino-6-(4-nitro-2,6-dimethylphenoxy)-1,3,5-triazine-2-il]amino]benzonitrile; 4-[[4-amino-6-(2,6-dibromo-4-methylphenoxy)-1,3,5-triazine-2-il]amino]benzonitrile; 4-[[4-amino-6-(4-formyl-2,6-dimethylphenoxy)-1,3,5-triazine-2-il]amino]benzonitrile; 4-[[4-amino-6-[(2,4-dichlorophenyl)thio]-1,3,5-triazine-2-il]amino]benzonitrile; 4-[[4-[(5-acetyl-2,3-dihydro-7-methyl-1H-inden-4-il)oxy)-6-amino-1,3,5-triazine-2-il-amino]benzonitrile; 4-[[4-amino-6-[(4-bromo-2-chloro-6-methylphenyl)amino]-1,3,5-triazine-2-il]amino]benzonitrile; 4-[[4-amino-6-[[2-chloro-4,6-dimethylphenyl)amino]-1,3,5-triazine-2-il]amino]benzonitrile; 4-[[4-amino-6-[[2,4-dichloro-6-(trifluoromethyl)phenyl)amino]-1,3,5-triazine-2-il]-amino]benzonitrile; 4-[[4-amino-6-[methyl(2,4,6-trimethylphenyl)amino]-1,3,5-triazine-2-il]amino]-benzonitrile; 4-[[4-amino-6-[[2,6-dibromo-4-methylphenyl)amino]-1,3,5-triazine-2-yl]amino]-benzonitrile; 4-[[4-amino-6-[[2,6-dibromo-4-(1-methylethyl)phenyl]amino]-1,3,5-triazine-2-yl]amino] benzonitrile; 4-[[4-amino-5-chloro-6-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]-benzonitrile; 4-[[5-chloro-4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile; 4-[[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]amino]benzonitrile; 4-[[4-amino-5-chloro-6-[(4-cyano-2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]-benzonitrile; 4-[[5-bromo-6-(4-cyano-2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile; 4-[[4-amino-5-chloro-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]amino]-benzonitrile; and 4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]amino]-benzonitrile; 4-[[4-[(2,4,6-trimethylphenyl)amino]-1,3,5-triazine-2-yl]amino]benzonitrile; N-oxide, pharmaceutically recognized addition salts and its stearic chemical isomers.

5. Use under any of the claims in clauses 1 through 4, whereby the compound 4-[[4-amino-5-bromo-6(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]amino]benzonitrile or 4[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile or 4-[[4-[(2,4,6,-trimethylphenyl)amino]-1,3,5-triazine-2-yl]amino]benzonitrile N-oxide, its salt, pharmaceutically acceptable addition, quaternary amine, or its stearioisomeric form.

6. Use under any of the claims in clauses 1 through 5, whereby the compound is 4-[[4-[(2,4,6-trimethylphening)amino]-2-pyrimidinyl]amino]benzonitrile N-oxide, its salts, its pharmaceutically acceptable additions, or its quaternary amines.

7. Use under any of the claims in clauses 1 through 6 where transmission or infection occurs through sexual intercourse or related close contact between partners.

8. Use under any of the claims in clauses 1 through 7 where the transmission or infection occurs through the vagina.

9. Use under any of the claims in clauses 1 through 8 where the drug is in a form for specific use only.

10. Use under any one of the claims 1 through 9 where the drug is biologically binding to the site of application.

11. Use under any of the claims in clauses 1 through 10 where the drug is in the form of a gel, jelly, cream, paste, emulsion, dispersion, ointment, film, sponge, foam, aerosol, powder, vaginal IUD, uterine cap, implant, patch, suppository, pessary, tablet, or mouthwash.

12. Use under any of the claims in clauses 1 through 10 where the drug is in the form of a delivery system that releases the drug immediately.

13. Use under any of the claims in clauses 1 through 10 where the drug is in the form of a sustained-release delivery system.

14. Under which claim is the usage permitted?